Form 8-K

8-K — STANDARD BIOTOOLS INC.

Accession: 0001193125-26-206395

Filed: 2026-05-05

Period: 2026-05-05

CIK: 0001162194

SIC: 3826 (LABORATORY ANALYTICAL INSTRUMENTS)

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — lab-20260505.htm (Primary)

EX-99.1 (lab-ex99_1.htm)

GRAPHIC (img96762296_0.gif)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: lab-20260505.htm · Sequence: 1

8-K

0001162194 false00011621942026-05-052026-05-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): May 5, 2026

Standard BioTools Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of

incorporation or organization)

001-34180

(Commission File Number)

77-0513190

(I.R.S. Employer Identification Number)

50 Milk Street, 10th Floor

Boston, Massachusetts 02109

(Address of principal executive offices and zip code)

(650) 266-6000

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common stock, $0.001 par value per share

LAB

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 - Results of Operations and Financial Condition

On May 5, 2026, Standard BioTools Inc. issued a press release which included information with respect to certain financial results for the three months ended March 31, 2026. The press release is attached hereto as Exhibit 99.1.

The information set forth in the press release, except for the information set forth under the headings “Full Year 2026 Revenue Outlook” and “About Standard BioTools Inc.”, together with the forward-looking statement disclaimer, is incorporated by reference into this Item 2.02 of this Current Report on Form 8-K.

Item 7.01 Regulation FD Disclosure

The information set forth under the headings “Full Year 2026 Revenue Outlook” and “About Standard BioTools Inc.”, together with the forward-looking statement disclaimer, is incorporated by reference into this Item 7.01 of this Current Report on Form 8-K.

Item 9.01 - Financial Statements and Exhibits

(d) Exhibits

Exhibit No.

Description

99.1

Press release issued by Standard BioTools Inc., dated May 5, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

The information in Item 2.02 and Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:

May 5, 2026

STANDARD BIOTOOLS INC.

By:

/s/ Alex Kim

Name:

Alex Kim

Title:

Chief Financial Officer

EX-99.1

Filename: lab-ex99_1.htm · Sequence: 2

EX-99.1

Exhibit 99.1

Standard BioTools Reports First Quarter 2026 Financial Results

BOSTON, Mass., May 5, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended March 31, 2026.

Recent Highlights:

•

First quarter 2026 revenue of $21.1 million

•

54% reduction in operating loss and 78% improvement in adjusted EBITDA year-over-year supporting path to positive adjusted EBITDA exiting 2026

•

$524 million in cash & investments as of March 31, 2026, excluding $25 million earnout received after quarter end, to fuel inorganic growth strategy

“We delivered a strong start to 2026, with first quarter performance coming in above expectations,” said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. “We are operating our base business with consistency, delivering year-over-year top-line growth, and our cost savings initiatives are taking hold with a 78% improvement in adjusted EBITDA to a loss of $3.1 million in the quarter, reinforcing our path to profitability in 2026.”

Dr. Egholm continued, “With the sale of SomaLogic to Illumina complete, we are fully focused on strategic capital deployment to transform the business. Our strong balance sheet, with approximately $550 million in cash and investments inclusive of a $25 million earnout received after quarter end, provides substantial flexibility to pursue attractive opportunities and create shareholder value.”

Financial Results Table: Continuing Operations

As Reported

Three Months Ended

(Unaudited, in millions, except percentages)

March 31, 2026

March 31, 2025

Revenue

21.1

20.2

Gross margin

53.5

54.6

Non-GAAP gross margin

57.7

57.1

Operating expenses

23.8

38.0

Non-GAAP operating expenses

15.3

25.6

Operating loss

(12.5

)

(27.0

)

Net loss from continuing operations

(14.6

)

(23.4

)

Adjusted EBITDA

(3.1

)

(14.1

)

Cash, cash equivalents, restricted cash, and liquid investments

523.6

260.7

First Quarter 2026 Financial Results: Continuing Operations

•

Revenue was $21.1 million in the first quarter of 2026, up 5% year-over-year.

•

Consumables revenue was $11.0 million in the first quarter of 2026, up 35% year-over-year. Greater consumables revenue in the quarter reflected growth across all product categories, primarily driven by microfluidics.

•

Instruments revenue was $4.5 million in the first quarter of 2026, down 33% year-over-year. Instrument revenue in the quarter, compared against particularly strong prior year results, remained impacted

by capital-constrained end-markets.

•

Services revenue, which is predominantly Field Services, was $5.7 million in the first quarter of 2026, up 5% year-over-year.

•

Gross margins in the first quarter of 2026 were approximately 53.5%, versus 54.6% in the first quarter of 2025; and non-GAAP gross margins in the first quarter of 2026 were approximately 57.7%, versus 57.1% in the first quarter of 2025. Gross margins and non-GAAP gross margins were driven by volume and product mix.

•

Operating expenses in the first quarter of 2026 were $23.8 million, a decrease of $14.2 million, or down 37%, compared to the first quarter of 2025. Operating expenses included $3.1 million in restructuring and related charges. Non-GAAP operating expenses, which exclude transaction costs, stock-based compensation, and restructuring charges, were $15.3 million in the first quarter of 2026, a decrease of $10.3 million, or down 40%, compared to the first quarter of 2025. The decrease in operating expenses was largely due to previously announced restructuring actions.

•

Net loss for the first quarter of 2026 was $14.6 million, compared to a net loss of $23.4 million in the first quarter of 2025, representing a change of $8.7 million or 37%. Adjusted EBITDA for the first quarter of 2026 was a loss of $3.1 million, versus an adjusted EBITDA loss of $14.1 million in the first quarter of 2025, an improvement of $11.0 million, or 78%.

Full Year 2026 Revenue Outlook

For fiscal year 2026, the Company continues to expect revenue in the range of $80 million to $85 million.

Use of Non-GAAP Financial Information

Standard BioTools has presented certain financial information in accordance with U.S. GAAP and on a non-GAAP basis. The non-GAAP financial measures included in this press release are non-GAAP gross margin, non-GAAP gross profit, non-GAAP operating expenses, and adjusted EBITDA. Management uses these non-GAAP financial measures, in addition to GAAP financial measures, as a measure of operating performance because the non-GAAP financial measures do not include the impact of items that management does not consider indicative of the Company’s core operating performance. Management believes that non-GAAP financial measures, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the Company’s core operating results. Management uses non-GAAP measures to compare the Company’s performance relative to forecasts and strategic plans and to benchmark the Company’s performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the Company’s operating results as reported under U.S. GAAP. Standard BioTools encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliations between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP financial measures are presented in the accompanying tables of this release.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding future financial and business performance, including with respect to the full year 2026 revenue outlook; the Company’s beliefs about future profitability; operational and strategic plans; deployment of capital; market and growth opportunity and potential; and the potential to realize the expected benefits from the transaction with Illumina and the expected benefits and synergies of prior and potential future acquisitions, including the potential for such transactions to drive long-term profitable growth. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including, but not limited to, the potential that the expected benefits and opportunities of the transaction may not be realized or may take longer to realize than expected; risks that the anticipated benefits and

synergies resulting from prior and potential future acquisitions and the integration of any such businesses, including the potential for such transactions to drive long-term profitable growth, may not be fully realized or may take longer to realize than expected; risks that the Company may not realize expected cost savings from such transactions; possible integration, restructuring and transition-related disruption resulting from such transactions, including through the loss of customers, suppliers, and employees and adverse impacts on the Company’s development activities and results of operation; integration and restructuring activities, including customer and employee relations, management distraction, and reduced operating performance; risks that internal and external costs required for ongoing and planned activities may be higher than expected, which may cause the Company to use cash more quickly than it expects or change or curtail some of the Company’s plans, or both; risks that the Company’s expectations as to expenses, cash usage, and cash needs may prove not to be correct for other reasons such as changes in plans or actual events being different than our assumptions; changes in the Company’s business or external market conditions; existing and potential future NIH funding pressures; the effect from existing and potential future U.S. export controls and tariffs; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; interruptions or delays in the supply of components or materials for, or manufacturing of, the Company’s products; reliance on sales of capital equipment for a significant proportion of revenues in each quarter; seasonal variations in customer operations; unanticipated increases in costs or expenses; continued or sustained budgetary, inflationary, or recessionary pressures; uncertainties in contractual relationships; reductions in research and development spending or changes in budget priorities by customers; uncertainties relating to the Company’s research and development activities, and distribution plans and capabilities; potential product performance and quality issues; risks associated with international operations; intellectual property risks; and competition. For information regarding other related risks, see the “Risk Factors” section of the Company’s annual report on Form 10-K, for the year ended December 31, 2025, filed with the SEC on March 16, 2026, the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2026, to be filed with the SEC, and in the Company’s other filings with the SEC. These forward-looking statements speak only as of the date hereof. The Company disclaims any obligation to update these forward-looking statements except as may be required by law.

About Standard BioTools Inc.

Standard BioTools, Inc. (Nasdaq: LAB), is committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world class management team. The Company's established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.

For Research Use Only. Not for use in diagnostic procedures.

Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.

Patent and License Information: standardbio.com/legal/notices.

Investor Contact:

ir@standardbio.com

STANDARD BIOTOOLS INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(Unaudited)

Three Months Ended March 31,

2026

2025

Revenue:

Product revenue

15,454

14,781

Services and other revenue

5,692

5,441

Total revenue

21,146

20,222

Cost of revenue:

Cost of product revenue

7,706

6,431

Cost of services and other revenue

2,132

2,742

Total cost of revenue

9,838

9,173

Gross profit

11,308

11,049

Operating expenses:

Research and development

2,117

5,440

Selling, general and administrative

18,607

29,824

Restructuring and related charges

3,080

1,552

Transaction and integration expenses

1,203

Total operating expenses

23,804

38,019

Loss from operations

(12,496

)

(26,970

)

Interest income, net

3,511

2,914

Other (expense) income, net

(5,630

)

567

Loss before income taxes

(14,615

)

(23,489

)

Income tax (expense) benefit

(11

)

119

Net loss from continuing operations

(14,626

)

(23,370

)

Discontinued operations:

Income (loss) from discontinued operations, net of tax

141,694

(2,663

)

Net income (loss)

127,068

(26,033

)

Net loss per share from continuing operations

(0.04

)

(0.06

)

Net income (loss) per share from discontinued operations

0.37

(0.01

)

Net income (loss) per share

0.33

(0.07

)

Shares used in computing net income (loss) per share attributable to common stockholders

388,202

378,228

STANDARD BIOTOOLS INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

(Unaudited)

March 31,

2026

December 31,

2025

ASSETS

Current assets:

Cash and cash equivalents

265,772

120,863

Short-term investments

189,404

66,712

Accounts receivable, net

16,637

13,431

Inventory

18,594

19,981

Prepaid expenses and other current assets

6,046

4,871

Contingent consideration receivable

25,000

—

Current assets held for sale

—

228,406

Total current assets

521,453

454,264

Property and equipment, net

17,103

19,275

Operating lease right-of-use asset, net

25,545

26,732

Other non-current assets

3,386

3,154

Long-term investments

71,357

25,701

Deferred tax asset, non-current

270

38,628

Total assets

639,114

567,754

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable

8,007

5,407

Accrued liabilities

15,684

29,783

Operating lease liabilities, current

5,540

5,490

Deferred revenue, current

9,981

38,949

Deferred grant income, current

2,991

3,046

Current liabilities held for sale

—

25,633

Total current liabilities

42,203

108,308

Convertible notes, non-current

299

Deferred tax liability

823

810

Operating lease liabilities, non-current

23,652

25,038

Deferred revenue, non-current

3,013

3,503

Deferred grant income, non-current

3,557

4,290

Other non-current liabilities

4,444

1,215

Total liabilities

77,991

143,463

Total stockholders’ equity

561,123

424,291

Total liabilities and stockholders’ equity

639,114

567,754

STANDARD BIOTOOLS INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Continuing and Discontinued Operations

(In thousands)

(Unaudited)

Three Months Ended March 31,

2026

2025

Operating activities

Net income (loss)

127,068

(26,033

)

Gain on sale of business

(172,289

)

—

Stock-based compensation expense

8,824

9,009

Amortization of acquired intangible assets

—

898

Depreciation and amortization

1,408

3,273

Accretion of discount on short-term investments, net

(632

)

(841

)

Unrealized loss on equity investments

3,494

—

Non-cash lease expense

1,355

1,438

Provision for excess and obsolete inventory

696

815

Change in fair value of warrants

—

(232

)

Change in fair value of contingent consideration

—

(3,400

)

Other non-cash items

385

Changes in assets and liabilities, net

(16,588

)

(15,595

)

Net cash used in operating activities

(46,597

)

(30,283

)

Investing activities

Cash received for sale of business, net

363,222

—

Purchases of short-term marketable debt securities

(127,208

)

(32,321

)

Purchases of long-term marketable debt securities

(58,517

)

—

Purchases of marketable equity securities

(837

)

—

Proceeds from sales and maturities of investments

15,000

52,000

Purchases of property and equipment

(570

)

(5,054

)

Net cash provided by (used in) investing activities

191,090

14,625

Financing activities

Payments for taxes related to net share settlement of equity awards and other

(118

)

(46

)

Proceeds from exercise of stock options

Net cash provided by (used in) financing activities

(40

)

(46

)

Effect of foreign exchange rate fluctuations on cash and cash equivalents

115

357

Net increase (decrease) in cash, cash equivalents and restricted cash

144,568

(15,347

)

Cash, cash equivalents and restricted cash at beginning of period

123,296

168,818

Cash, cash equivalents and restricted cash at end of period

267,864

153,471

Cash, cash equivalents, and restricted cash consists of:

Cash and cash equivalents

265,772

150,880

Restricted cash

2,092

2,591

Total cash, cash equivalents and restricted cash

267,864

153,471

STANDARD BIOTOOLS INC.

REVENUE

Continuing Operations

(In thousands)

(Unaudited)

Three Months Ended March 31,

2026

2025

Product revenue:

Instruments

4,470

6,646

Consumables

10,984

8,135

Total product revenue

15,454

14,781

Services and other revenue

5,692

5,441

Total revenue

21,146

20,222

STANDARD BIOTOOLS INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION

Continuing Operations

(In thousands)

(Unaudited)

ITEMIZED RECONCILIATION OF GROSS PROFIT TO NON-GAAP GROSS PROFIT AND MARGIN PERCENTAGE

Three Months Ended March 31,

2026

2025

Gross profit

11,308

11,049

Amortization of acquired intangible assets

—

Depreciation and amortization

346

263

Stock-based compensation expense

541

242

Non-GAAP gross profit

12,195

11,554

Gross margin percentage

53.5

54.6

Amortization of acquired intangible assets

—

Depreciation and amortization

1.6

1.3

Stock-based compensation expense

2.6

1.2

Non-GAAP gross margin percentage

57.7

57.1

STANDARD BIOTOOLS INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION

Continuing Operations

(In thousands)

(Unaudited)

ITEMIZED RECONCILIATION OF GAAP TO NON-GAAP OPERATING EXPENSES

Three Months Ended March 31,

2026

2025

Operating expenses

23,804

38,019

Restructuring and related charges

(3,080

)

(1,552

)

Transaction and integration expenses

(1,203

)

Stock-based compensation expense

(4,460

)

(7,807

)

Depreciation and amortization

(1,016

)

(1,826

)

Gain on disposal of property and equipment

—

Non-GAAP operating expenses

15,282

25,631

R&D operating expenses

2,117

5,440

Stock-based compensation expense

(162

)

(339

)

Depreciation and amortization

(168

)

(139

)

Gain on disposal of property and equipment

(28

)

Non-GAAP R&D operating expenses

1,787

4,934

SG&A operating expenses

18,607

29,824

Stock-based compensation expense

(4,298

)

(7,468

)

Depreciation and amortization

(848

)

(1,687

)

Gain on disposal of property and equipment

Non-GAAP SG&A operating expenses

13,495

20,697

STANDARD BIOTOOLS INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION

Continuing Operations

(In thousands)

(Unaudited)

ITEMIZED RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA

Three Months Ended March 31,

2026

2025

Net loss from continuing operations

(14,626

)

(23,370

)

Income tax (benefit) expense

(119

)

Interest income, net

(3,511

)

(2,914

)

Depreciation and amortization

1,362

2,089

Restructuring and related charges

3,080

1,552

Transaction and integration expenses

—

1,203

Stock-based compensation expense

5,001

8,049

Gain on disposal of property and equipment

(34

)

—

Other non-operating expense (income)

5,630

(567

)

Adjusted EBITDA

(3,087

)

(14,077

)

GRAPHIC

Filename: img96762296_0.gif · Sequence: 3

Binary file (30377 bytes)

Download img96762296_0.gif

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 6

v3.26.1

Cover

May 05, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 05, 2026

Entity File Number

001-34180

Entity Registrant Name

Standard BioTools Inc.

Entity Central Index Key

0001162194

Entity Tax Identification Number

77-0513190

Entity Incorporation, State or Country Code

Entity Address, Address Line One

50 Milk Street

Entity Address, Address Line Two

10th Floor

Entity Address, City or Town

Boston

Entity Address, State or Province

Entity Address, Postal Zip Code

02109

City Area Code

650

Local Phone Number

266-6000

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common stock, $0.001 par value per share

Trading Symbol

LAB

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration